The global riboflavin corneal crosslinking pharmaceutical market was valued at USD 185.0 million in 2025 and is estimated at USD 200.7 million in 2026. The market is projected to reach USD 385.0 million by 2034, representing an 8.5% CAGR during 2026–2034. The report measures first-sale revenue for specified riboflavin corneal crosslinking material or formulation, excluding related...